CTO 2.0 Newly Released

Clinical Trial Optimization

What is Clinical Trial Optimization?

CTO 2.0 is a large-population AI SaaS solution for clinical trial design and optimization in oncology and hematology.

Powered by the largest research data repository covering 900+ providers and research sites.

Build and optimize legacy and new studies with unlimited Inclusion and Exclusion criteria.

Cohorts can be assessed with line of therapy tools, Kaplan-Meier Survival Curves, and Cox Proportional Hazard scores.

CTO 2.0 is the most advanced solution for trial diversity and study-specific strategies, using EMR and Medical-claims linked to Social Determinants of Health.

CTO 2.0 Now Available!

CTO 2.0 as a unique Data-as-a-Service and AI Software-as-a-Service solution we are optimizing scale and functionality for clinical, clinical trial analytics, and clinical operations teams.

Left image

Button 1
Button 2
Button 3
High Depth
Clinical Data
Three-part integrated data, with an EMR foundation for diagnosis and treatments, linked to medical claims and social determinants of health assure all aspects of populations and sites can be assessed.
Trial
Diversity
FDA imperatives for trial populations to be more similar to the ultimate treated population and for greater diversity is assured in our trial modeling  and AI for designs, cohorts and research sites
Research Site
& Patient Burden
Greater use of research capable community sites means designing to the level of clinical activities of the standard of care in those settings.  Our burden scoring and optimizations assure that.
Biomarkers

Curated molecular and other data from multiple sources assure trial modeling can see treatment sequencing and diagnostic use across settings.

Dynamically Assess
Trial Enrollment Feasibility
and Select Optimal Sites

“Our Feasibility team would stage a coup if we stopped license, in a short time you have become a critical part of our clinical research site selection process”

– CRO Client

“We have our current go-to trial feasibility solution, but discovered that your software and data is a much better fit for our Oncology trials feasibility needs”

– Large Pharma Client

Key Benefits

Assure study I/E criteria, optimized burden, and tightly synched site capabilities drive productivity and time benefits
Identify sites with specific alignment to study, identifying 30 to 60% greater research capable sites than were used in legacy approaches
Build Trial Generalizability and Diversity Strategies and implement these at the program, study and site levels.
Access Study Feasibility with RWD and AI Historical trends & AI-driven prediction of future performance of study at sites
Request a Demo

 

 

Trial Feasibility

 

Accelerate trial planning – iteratively evaluate protocol’s inclusion/exclusion criteria against ConcertAI’s industry-leading real-world data

 

 

Cohort Optimization

 

User specifies target trial objectives and AI algorithm analyzes trade-offs and provides suggestions on study criteria changes to meet the objectives

 

 

Patient Burden Analysis

 

Assess how your current study design compares to standard of care leveraging retrospective real-world data

 

 

Treatment Pathways

 

Visually inspect lines of therapy and associated patient counts using a Sankey diagram

 

 

Site Selection

 

Review up-to-date list of sites with their historical clinical trial activity along with AI-driven prediction of future performance

ConcertAI Publications

Click an image below to read more about ConcertAI academic publications supporting Clinical Trial Optimization

Cohort Optimizer, a Software Solution That Uses Real-World Data and AI to Optimize Criteria of Oncology Trials

Evaluating the Impact of Performance Status Criteria on Minority Eligibility
for Oncology Clinical Trials

Impact of Trial Site Selection
on Minority Patient Recruitment
in Prostate Cancer Trials

Learn More About ConcertAI’s

Clinical Trial Optimization